March 18, 2021
Gallinger brings more than three decades of clinical and interdisciplinary research experience to OICR leadership
Dr. Steven Gallinger has joined OICR’s executive leadership team as Head, Clinical Translation. In this role, he will lead one of OICR’s three key priority areas, Clinical Translation, which focuses on advancing Ontario cancer discoveries through early clinical validation, partnering with industry and the health system for downstream development and implementation.
Gallinger has more than three decades of experience as a surgical oncologist specializing in hepato-pancreatico-biliary surgeries. He is internationally recognized for establishing one of the largest population-based colon cancer registries, and he is well-known for his pancreatic cancer research, through which he has made significant contributions to large-scale genomics studies like the International Cancer Genome Consortium. Gallinger is passionate about building large biospecimens and data repositories to enable research discoveries.
In conjunction with Gallinger’s appointment, OICR is also proud to announce Dr. Glenn Bauman will continue as a Clinical Lead for Clinical Translation. Bauman, who has led several OICR research initiatives and clinical trials over the last 10 years, is a Radiation Oncologist at the London Health Sciences Centre who focuses on genitourinary and central nervous system tumours.
“The entire OICR executive is thrilled to have Dr. Gallinger join our leadership team,” says Dr. Laszlo Radvanyi, President and Scientific Director, OICR. “Steven’s deep experience as both a clinician and researcher will help OICR strengthen our bridge between the lab and the clinic. The continued contributions of Dr. Bauman will further accelerate our efforts to get novel solutions to patients in Ontario and around the world.”
“Translating research findings to improve clinical care is complex,” says Dr. Christine Williams, Deputy Director, OICR. “Success depends on the engagement of many partners, including the health system, health regulators and in some cases the private sector, as well as scientists, clinicians and especially patients and their families. Drs. Gallinger and Bauman are leaders in forging these partnerships and translating research into practice. We’re proud to welcome Dr. Gallinger to OICR’s executive team and delighted that OICR will continue to benefit from Dr. Bauman’s scientific leadership.”
Among his many career accomplishments, Gallinger and the multidisciplinary team at Princess Margaret has been the driving force behind the COMPASS clinical trial, which has led to seminal discoveries that are paving the way for new personalized pancreatic cancer therapies. As Head of Clinical Translation, Gallinger will continue co-leading the pancreatic cancer PanCuRx Translational Research Initiative and build upon PanCuRx’s translational achievements.
“This is an exciting time at OICR,” says Gallinger. “We’re looking to build on our existing networks and research successes. As we embark upon our new Strategic Plan, I think we can reach out and support research across more cancer centres so that we can work together to benefit patients sooner, while keeping Ontario at the forefront of precision cancer medicine.”
As part of her Deputy Director role, Williams will continue to oversee the Clinical Translation networks of the Clinical Translation portfolio, including the Canadian Cancer Clinical Trials Network, the Ontario Cancer Research Ethics Board and the Ontario Health Study.